Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Boston Scientific Corp (BSX)

Boston Scientific Corp (BSX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 65,757,400
  • Shares Outstanding, K 1,432,311
  • Annual Sales, $ 11,888 M
  • Annual Income, $ 1,041 M
  • 60-Month Beta 0.83
  • Price/Sales 5.25
  • Price/Cash Flow 17.14
  • Price/Book 3.76
Trade BSX with:

Options Overview Details

View History
  • Implied Volatility 24.42% ( -0.17%)
  • Historical Volatility 15.57%
  • IV Percentile 13%
  • IV Rank 11.45%
  • IV High 44.03% on 03/01/22
  • IV Low 21.89% on 08/18/22
  • Put/Call Vol Ratio 0.20
  • Today's Volume 1,347
  • Volume Avg (30-Day) 6,539
  • Put/Call OI Ratio 1.54
  • Today's Open Interest 121,061
  • Open Int (30-Day) 134,218

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate 0.47
  • Number of Estimates 11
  • High Estimate 0.50
  • Low Estimate 0.46
  • Prior Year 0.45
  • Growth Rate Est. (year over year) +4.44%

Price Performance

See More
Period Period Low Period High Performance
1-Month
44.35 +3.52%
on 01/11/23
46.79 -1.88%
on 01/13/23
-0.33 (-0.71%)
since 12/27/22
3-Month
40.93 +12.16%
on 11/03/22
47.95 -4.25%
on 12/13/22
+4.33 (+10.41%)
since 10/27/22
52-Week
34.98 +31.25%
on 06/16/22
47.95 -4.25%
on 12/13/22
+2.68 (+6.20%)
since 01/27/22

Most Recent Stories

More News
Earnings Preview: SurModics (SRDX) Q1 Earnings Expected to Decline

SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SRDX : 26.68 (+1.25%)
BSX : 45.91 (-0.95%)
Boston Scientific (BSX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Boston Scientific (BSX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BSX : 45.91 (-0.95%)
BOSTON SCIENTIFIC INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Boston Scientific Corporation - BSX

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into Boston Scientific...

BSX : 45.91 (-0.95%)
Here's Why You Should Retain Boston Scientific (BSX) Now

Investors are optimistic about Boston Scientific (BSX) on recent acquisitions and robust performance of the WATCHMAN device.

BSX : 45.91 (-0.95%)
OFIX : 21.22 (-0.93%)
MMSI : 69.94 (+0.60%)
AMN : 96.32 (-2.65%)
Will Boston Scientific (BSX) Beat Q4 Earnings Estimates?

Boston Scientific (BSX) is expected to have registered strong growth in EMEA within structural heart, including TAVR, WATCHMAN, and other interventional cardiology therapies.

BSX : 45.91 (-0.95%)
LH : 254.30 (+0.04%)
CAH : 76.48 (-1.80%)
HOLX : 82.79 (-0.17%)
Charles River (CRL) to Develop RNA-based Therapy With New Pact

Charles River's (CRL) new partnership will enable the clinical development of RNA-based anticancer gene therapy in liver cancer patients.

BSX : 45.91 (-0.95%)
CRL : 245.09 (+0.33%)
MMSI : 69.94 (+0.60%)
AMN : 96.32 (-2.65%)
IDEXX (IDXX) Aided by Global Growth, Solid Instrument Placement

IDEXX's (IDXX) rapid assay revenue growth is supported by solid volume gains in the United States and benefits from net price increases.

BSX : 45.91 (-0.95%)
MMSI : 69.94 (+0.60%)
IDXX : 487.00 (unch)
AMN : 96.32 (-2.65%)
APOLLO ENDOSURGERY INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apollo Endosurgery, Inc. - APEN

/PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the...

APEN : 9.83 (-0.20%)
BSX : 45.91 (-0.95%)
Charles River (CRL) to Advance DNA Programs With New Launch

Charles River's (CRL) launch of the eXpDNA plasmid manufacturing platform is intended to support vaccine and advanced therapy clients through clinical trials and beyond.

BSX : 45.91 (-0.95%)
CRL : 245.09 (+0.33%)
MMSI : 69.94 (+0.60%)
AMN : 96.32 (-2.65%)
NuVasive (NUVA) Suffers From Macro Headwinds, Price Issue

NuVasive (NUVA) believes that its 2022 guidance is appropriately conservative, considering macroeconomic pressures on net sales and operating profit.

BSX : 45.91 (-0.95%)
MMSI : 69.94 (+0.60%)
AMN : 96.32 (-2.65%)
NUVA : 45.91 (+2.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments - Cardiovascular, Rhythm and...

See More

Key Turning Points

3rd Resistance Point 46.88
2nd Resistance Point 46.61
1st Resistance Point 46.26
Last Price 45.91
1st Support Level 45.65
2nd Support Level 45.38
3rd Support Level 45.03

See More

52-Week High 47.95
Last Price 45.91
Fibonacci 61.8% 43.00
Fibonacci 50% 41.47
Fibonacci 38.2% 39.93
52-Week Low 34.98

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar